Michaela Liedtke

Hematologist, Medical oncologist, Multiple myeloma specialist, Leukemia specialist

Assistant Professor of Medicine (Hematology) and, by courtesy, of Pathology at the Stanford University Medical Center

Hematology Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Amyloid Center

  • 300 Pasteur Drive
  • Stanford, CA 94305
  • Phone: 650-725-6186
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Fellowship: Memorial Sloan-Kettering Cancer Center (2004) NY

Board Certification: Medical Oncology, American Board of Internal Medicine (2006)

Board Certification: Hematology, American Board of Internal Medicine (2005)

Fellowship: Stanford University Medical Center (2005) CA

Residency: Albert Einstein College of Medicine (2002) NY

Medical Education: Medizinische Hochschule Hannover (1994) Germany

Honors & Awards

Translational Research Award, Stanford Department of Medicine (2011)

Young Investigator Award, ASCO (2008)

Research grant, Hope Street Kids Foundation (2006)

Methods in Clinical Cancer Research Scholar, ASCO/AACR (2005)

Fellowship Award, Lymphoma Research Foundation (2004)

Translational Research Award, Doris Duke Foundation (2004)

Administrative Appointments

Member, Stanford Amyloid Center (2010 - Present)

Member Leukemia Committee, Southwest Oncology Group (2011 - Present)

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Indolent T-lymphoblastic Proliferation With Disseminated Multinodal Involvement and Partial CD33 Expression.
Ohgami, R. S., Sendamarai, A. K., Atwater, S. K., Liedtke, M., Fleming, M. D., & Warnke, R. A. (2014). Indolent T-lymphoblastic Proliferation With Disseminated Multinodal Involvement and Partial CD33 Expression. American journal of surgical pathology, 38(9), 1298-1304.

Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia
Dinner, S., Lee, D., & Liedtke, M. (2014). Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia. LEUKEMIA & LYMPHOMA, 55(8), 1715-1724.

Effects of serum and plasma matrices on multiplex immunoassays
Rosenberg-Hasson, Y., Hansmann, L., Liedtke, M., Herschmann, I., & Maecker, H. T. (2014). Effects of serum and plasma matrices on multiplex immunoassays. IMMUNOLOGIC RESEARCH, 58(2-3), 224-233.

Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis
Varr, B. C., Zarafshar, S., Coakley, T., Liedtke, M., Lafayette, R. A., & Witteles, R. M. (2014). Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. HEART RHYTHM, 11(1), 158-162.

A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia
Patel, S., Liedtke, M., Ngo, D., & Medeiros, B. C. (2013). A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia. LEUKEMIA & LYMPHOMA, 54(10), 2231-2235.

Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement
Dinner, S., Witteles, W., Afghahi, A., Witteles, R., Arai, S., & Liedtke, M. (2013). Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. HAEMATOLOGICA, 98(10), 1593-1599.

AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin
Penchala, S. C., Connelly, S., Wang, Y., Park, M. S., Zhao, L., & Alhamadsheh, M. M. (2013). AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 110(24), 9992-9997.

The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis
Dinner, S., Witteles, W., Witteles, R., Lam, A., Arai, S., & Liedtke, M. (2013). The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. BRITISH JOURNAL OF HAEMATOLOGY, 161(3), 367-372.

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia
Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., & Medeiros, B. C. (2013). Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. HAEMATOLOGICA, 98(4), 591-596.

Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Cohen, A. D., & Kumar, R. (2013). Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(1), 11-17.

Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study
Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., & Liedtke, M. (2012). Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study. BLOOD, 120(21).

A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma
Dunn, T. J., Dinner, S. N., Berube, C., Gotlib, J., Coutre, S. E., & Liedtke, M. (2012). A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma. BLOOD, 120(21).

Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia
Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., & Advani, A. S. (2012). Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 87(10), 957-960.

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., & Medeiros, B. C. (2012). Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. LEUKEMIA, 26(5), 893-901.

More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis
Stevenson, R., Witteles, R., Damrose, E., Arai, S., Lafayette, R. A., & Liedtke, M. (2012). More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 138(5), 509-511.

Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies
Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., & Witteles, R. M. (2012). Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 31(3), 325-331.

Hemophagocytic lymphohistiocytosis in pregnancy: A case report and review of treatment options.
Dunn, T., Cho, M., Medeiros, B., Logan, A., Ungewickell, A., & Liedtke, M. (2012). Hemophagocytic lymphohistiocytosis in pregnancy: A case report and review of treatment options. Hematology (Amsterdam, Netherlands).

Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia
Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., & Coutre, S. E. (2012). Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 30-37.

The Transcription Factor Encyclopedia
Yusuf, D., Butland, S. L., Swanson, M. I., Bolotin, E., Ticoll, A., & Wasserman, W. W. (2012). The Transcription Factor Encyclopedia. GENOME BIOLOGY, 13(3).

A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML)
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Berube, C., Coutre, S., & Medeiros, B. C. (2010). A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML). BLOOD, 116(21), 1347-1347.

Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification
Medeiros, B. C., Kohrt, H. E., Rajwanshi, R., Gotlib, J., Coutre, S., & Zehnder, J. L. (2010). Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification. BLOOD, 116(21), 1357-1358.

Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., & Medeiros, B. C. (2010). Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. AMERICAN JOURNAL OF HEMATOLOGY, 85(11), 877-881.

Plasma cell leukemia: concepts and management.
Liedtke, M., & Medeiros, B. C. (2010). Plasma cell leukemia: concepts and management. Expert review of hematology, 3(5), 543-549.

Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6
Liedtke, M., Ayton, P. M., Somervaille, T. Cp., Smith, K. S., & Cleary, M. L. (2010). Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6. BLOOD, 116(1), 63-70.

Therapeutic targeting of MLL
Liedtke, M., & Cleary, M. L. (2009). Therapeutic targeting of MLL. BLOOD, 113(24), 6061-6068.

Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma
Kohrt, H., Logan, A., Temmins, C., Witteles, R., Liedtke, M., & Medeiros, B. (2008). Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma. LEUKEMIA & LYMPHOMA, 49(3), 581-585.

Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population
Liedtke, M., Hamlin, P. A., Moskowitz, C. H., & Zelenetz, A. D. (2006). Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. ANNALS OF ONCOLOGY, 17(6), 909-913.

Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase
Liedtke, M., Pandey, P., Kumar, S., KHARBANDA, S., & Kufe, D. (1998). Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase. ONCOGENE, 17(15), 1889-1892.

A SITE-DIRECTED MUTAGENESIS STUDY TO IDENTIFY AMINO-ACID-RESIDUES INVOLVED IN THE CATALYTIC FUNCTION OF THE RESTRICTION ENDONUCLEASE ECORV
SELENT, U., RUTER, T., Kohler, E., Liedtke, M., THIELKING, V., & Pingoud, A. (1992). A SITE-DIRECTED MUTAGENESIS STUDY TO IDENTIFY AMINO-ACID-RESIDUES INVOLVED IN THE CATALYTIC FUNCTION OF THE RESTRICTION ENDONUCLEASE ECORV. BIOCHEMISTRY, 31(20), 4808-4815.